Literature DB >> 30023102

Minimally invasive surgery is best treatment for early lung cancer.

Scott J Swanson1.   

Abstract

Entities:  

Year:  2018        PMID： 30023102      PMCID： PMC6036013          DOI： 10.21037/jtd.2018.04.171

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  3 in total

1.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

2.  Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than stereotactic body radiotherapy for clinical stage I lung cancer.

Authors:  Lorraine D Cornwell; Alfredo E Echeverria; Jason Samuelian; Jessica Mayor; Roberto F Casal; Faisal G Bakaeen; Shuab Omer; Ourania Preventza; Weiyuan Mai; George Chen; Katherine H Simpson; Drew Moghanaki; Angela W Zhu
Journal:  J Thorac Cardiovasc Surg       Date:  2017-08-16       Impact factor: 5.209

3.  Focal exposure of limited lung volumes to high-dose irradiation down-regulated organ development-related functions and up-regulated the immune response in mouse pulmonary tissues.

Authors:  Bu-Yeo Kim; Hee Jin; Yoon-Jin Lee; Ga-Young Kang; Jaeho Cho; Yun-Sil Lee
Journal:  BMC Genet       Date:  2016-01-27       Impact factor: 2.797
  3 in total
  1 in total

1.  Collaborating to assess the role of stereotactic body radiation therapy in medically operable stage I non-small cell lung cancer.

Authors:  Lorraine D Cornwell; Drew Moghanaki
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.